News & Updates
Filter by Specialty:
Show Multimedia Only

Inhaled amikacin cuts VAP burden in mechanically ventilated patients
16 Jan 2024
byAudrey Abella
In critically ill patients who have been on invasive mechanical ventilation (IMV) for at least 3 days, a subsequent 3-day course of preventive inhaled amikacin reduced the burden of ventilator-associated pneumonia (VAP) during 28 days of follow-up, findings from the AMIKINHAL trial have shown.